Published Aug 12, 2026
AEON Biopharma Q1 2026: The BOTOX Biosimilar Clears the First FDA Gate Into a Looming Cash Crunch
In-depth research on AEON covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,728 words17 min read
Read report